Please login to the form below

Not currently logged in

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Merck licences MS brain training programme

Strikes deal with HAPPYneuron to bolster its MSdialog platform for Rebif


Merck has struck a deal for a brain training eHealth system for people living with multiple sclerosis (MS) it will combine with its existing adherence service.

The German pharma company will include the HAPPYneuron programme within its MSdialog web-based software, giving the combined system a phased rollout, beginning first with Brazil, Argentina, Israel, Italy, France and the Netherlands.

Rehan Verjee, chief marketing and strategy officer of Merck's biopharma business, said: “We have a long-standing commitment to delivering therapeutic and support solutions to people living with MS. 

“The platform will enhance the attractiveness of MSdialog to patients and HCPs by seeking to address these cognitive deficit symptoms and further fostering the monitoring of the cognitive state of patients.”

HAPPYneuron's 'cognitive remediation' programme aims to improve patients' cognitive skills through brain training with repeated cognitive game training exercises.

The games are designed to address the cognition challenges people with MS face, with the games' difficulty automatically adjusting to match the need of the patient.

Merck signed an exclusive licence for the system - for an undisclosed amount - from France's HAPPYneuron, which is part of the SBT Group.

HAPPYneuron president Franck Tarpin-Bernard said: “This agreement is a strong acknowledgement of the hard work we have achieved these past years to build training programs adapted to the uniqueness of each medical condition. It reinforces our willingness to become a world leader of digital cognitive remediation.”

HAPPYneuron will be added to Merck's MSdialog, a cloud-based software system that records patient outcome data and provides patients prescribed the firm's Rebif (interferon beta-1a) treatment with reminders to take it.

13th June 2016

From: Marketing



Featured jobs

Subscribe to our email news alerts


Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...